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experimental acute volume overload
Introduction
Acute tricuspid valve regurgitation and atrial or ventricular 
rupture of the cardiac septum may lead to acute volume over-
load (AVO), resulting in cardiac failure and increased cardiac 
oxygen consumption (1). There is increasing awareness of the 
prognostic significance of right-sided heart congestion during 
AVO and acute cardiac failure (2). Low coronary perfusion pres-
sure associated with acute right-sided heart congestion leads to 
cardiac remodeling triggered by myocardial oxygen deprivation 
generating reactive oxygen species (ROS) (3). Developing myo-
cardial pressure due to ventricle volume overload may cause 
progressive myocardial ischemia (4).
Myocardial ischemia is associated with an increase in ROS 
production originating from several enzyme systems, such as 
oxidases of nicotinamide adenine dinucleotide phosphatase 
(NADPH), xanthine oxidase, electron leakage from the mitochon-
drial respiratory chain, cyclooxygenases, and uncoupled endo-
thelial nitric oxide synthase. Among these, monoamine oxidases 
(MAOs) have recently been under intense investigation and 
may contribute to vascular dysfunction after volume overload 
(5). MAOs are located in the outer mitochondrial membrane and 
have been shown to act against the arterial wall during ischemia 
by generating ROS during the oxidative breakdown of key neu-
rotransmitters, such as norepinephrine, epinephrine, and dopa-
mine (6). Mitochondrial MAOs are flavoproteins that exist in two 
isoforms (MAO-A and MAO-B) that are involved in the metabo-
lism of biogenic amines in vascular cells during oxidative stress 
and are distinguished by different substrate specificities and 
inhibitor sensitivities (6, 7). MAO-A activates the sphingolipid 
pathway (7), and MAO inhibitors may have therapeutic potential 
in myocardial hypertrophy and cardiac failure (8, 9). Among a 
few other research groups, we have previously shown that mo-
clobemide (Mo), an MAO-A inhibitor, ameliorates recovery after 
ischemia (10).
Objective: The molecular pathway leading to myocardial cellular destruction after acute volume overload (AVO) may include monoamine oxidases. 
The aim of the present study was to investigate whether moclobemide (Mo), a monoamine oxidase inhibitor, protects the myocardium after AVO.
Methods: Sixty syngeneic Fischer rats underwent surgical abdominal aortocaval fistula to induce AVO. Eighteen rats were treated with Mo 10 
mg/kg/day and were compared with 42 untreated rats with AVO without treatment. Myocardial recovery was analyzed using quantitative reverse 
transcription polymerase chain reaction for hypoxia-inducible factor 1-alpha, inducible nitric oxide synthase, interleukin 6, E-selectin, atrial 
natriuretic peptide (ANP), brain natriuretic peptide, vascular endothelial growth factor-alpha, matrix metalloproteinase 9, chitinase 3-like protein 
(YKL-40), and transforming growth factor-beta.
Results: After 3 days, the relative number of ischemic intramyocardial arteries in the left ventricle was lower in AVO treated with Mo than in 
without [0.04 (0.02–0.07) vs. 0.09 (0.07–0.14), point score unit]. After 1 day, ANP was lower in AVO treated with Mo than in without [0.95 (0.37–1.84) 
vs. 2.40 (1.33–3.09), fold changes from the baseline (FC), p=0.044], whereas after 1 and 3 days, YKL-40 was higher in AVO treated with Mo than in 
without [22.66 (14.05–28.83) vs. 10.06 (6.23–15.02), FC, p=0.006 and 6.03 (4.72–7.18) vs. 3.70 (2.62–5.35), FC, p=0.025].
Conclusion: Mo decreases intramyocardial arterial ischemia of the left ventricle after AVO while increases YKL-40, reflecting cellular protection dur-
ing early cardiac remodeling. In the future, adding Mo may be a simple means for myocardial protection after AVO. (Anatol J Cardiol 2019; 21: 39-45)
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We hypothesized that Mo impacts the myocardial arteries 
early after AVO in a rat model simulating the clinical scenario of 
acute cardiac insufficiency by performing a surgical 5 mm long 
abdominal aortocaval fistula. The aim of the present study was to 
investigate the effect of Mo on acute myocardial changes after 
experimental AVO with the aid of chitinase 3-like protein (YKL-40) 
that interacts with cell proliferation, differentiation, inflammation, 
and remodeling of the extracellular matrix and inhibits apoptosis 
(11). To demonstrate the validity of our model, atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP) were investi-
gated; these cardiac hormones represent compensation of con-
gestive heart failure due to their vasodilating, antiproliferative, and 
neurohumoral-modulating capacities (12). Myocardial inflamma-
tion and remodeling was analyzed with hypoxia-inducible factor 
1-alpha (HIF1α) (13), inducible nitric oxide synthase (iNOS), in-
terleukin 6 (IL-6), E-selectin, vascular endothelial growth factor-
alpha (VEGFα), matrix metalloproteinase 9 (MMP9), CD68 for mac-
rophages, and transforming growth factor-beta (TGFβ).
Methods
Rats
Sixty Fischer 344 rats (F344/NHsd; Harlan Laboratories, The 
Netherlands) weighing 200–350 g underwent surgical abdomi-
nal arterial–venous fistula to induce AVO, with six normal hearts 
from non-operated rats serving as controls. The rats were kept 
in the University of Tampere vivarium and received humane care 
in compliance with the “Principles of Laboratory Animal Care” 
formulated by the National Society for Medical Research and the 
“Guide for the Care and Use of Laboratory Animals” prepared by 
the Institute of Laboratory Animal Resources and published by the 
National Institutes of Health (publication no. 86-23, revised 1996). 
The study was approved by the Finnish State Provincial Office.
Surgical procedure
Rats were anesthetized with sevoflurane (Baxter, USA) for 
inhalation and pentobarbiturate (50 mg/kg, Mebunat vet®; Orion, 
Espoo, Finland) intraperitoneally. The abdominal cavity was sur-
gically opened, and the inferior vena cava and the aorta were 
exposed. An arterio-venous fistula was performed intra-abdomi-
nally by incising vertically 5 mm both the abdominal aorta and the 
adjacent inferior vena cava and joining these vessels surgically 
with a 7-0 running vascular suture. After surgery, 100 U Heparin 
Leo (Vianex S.A., Greece) was administered intravenously. From 
the abdominal aorta, oxygenated blood was introduced into the 
abdominal vena cava, thus resulting in AVO of the heart. The sur-
gical procedure was confirmed by observing the immediate in-
ferior vena cava circulating blood color change from dark blue to 
pale blue proximal to the created arterio-venous fistula. The pul-
sation of arterial blood was both visualized and palpated on the 
inferior vena cava proximal adjacent to the fistula. This model 
allowed the study of extensive AVO and associated myocardial 
changes in vivo. The model thus simulated the clinical concept 
of volume overload without ischemia (14). After the procedure, 
buprenorphine (0.1 mg/100 g, Vetergesic®; Orion) and carprofen 
(0.5 mg/100 g, Norocarp®; Norbrook Laboratories Limited, Ne-
wry, Northern Ireland) were given subcutaneously for pain relief. 
Sixty syngeneic Fischer rats underwent surgical abdominal aor-
tocaval fistula to induce AVO. Among these, 18 rats were treated 
with Mo 10 mg/kg/day by subcutaneous injection (AVO+Mo), and 
42 rats with AVO were left untreated for comparison.
Tissue samples
The rats were sacrificed 1 (n=32) or 3 (n=16) days after AVO, 
whereas 12 rats were lost due to acute cardiac failure. Six nor-
mal hearts from non-operated rats were also obtained. The bas-
al part of the hearts was separated and stored in RNA later (Ap-
plied Biosystems, CA, USA) for quantitative reverse transcription 
polymerase chain reaction (RT-PCR) analysis. The apex part of 
the heart was fixed in formalin and embedded in paraffin.
Histology
For histology, 5 µm sections were cut and stained with he-
matoxylin and eosin. The presence of subendocardial and myo-
cardial edema, hemorrhage, and ischemia was evaluated from 
all samples. As the vacuolization of the nuclei in the medial layer 
of the intramyocardial arteries reflects edema, a representative 
cross-sectional intramyocardial artery was selected randomly 
from both the left anterior, septum, and right posterior ventricu-
lar walls. Normal, edematous, and sharp-edged medial cell nu-
clei were manually counted separately. The relative number of 
ischemic nuclei of intramyocardial arteries was calculated by 
dividing the total number of sharp-edged medial cell nuclei by 
the normal round-shaped nuclei. The presence of periadventitial 
inflammatory cells was graded according to an arbitrary scale 
from 0 to 1, with 0, no inflammation and 1, presence of inflam-
mation. The evaluation of the histology was performed by two 
investigators blinded to the study protocol.
Immunohistochemistry
Immunohistochemistry was performed to three untreated 
controls and three hearts after AVO with Mo using Ventana Life-
sciences Benchmark XT© Staining module. The paraffin-embed-
ded slides were deparaffinized with three changes of xylene, rehy-
drated in a series of graded ethanol, and rinsed well under running 
distilled water. The slides were placed in a preheated retrieval 
buffer, 0.1 mmol EDTA, pH 8.0, for 30 min and then cooled in a buffer 
for 5 min, followed by a 5-minute rinse under running distilled wa-
ter. After heat-induced epitope retrieval, the slides were placed 
on an autostainer (DAKO Corp., Carpinteria, CA, USA). Sections 
were incubated with 3% hydrogen peroxide in ethanol for 5 min 
to inactivate the endogenous peroxides and incubated in CD68 
antibody (dilution 1:100) (Biomedica Gruppe, Germany) or YKL-40 
antibody (dilution 1:100) (Biomedica Gruppe) for 30 min, followed 
by rinsing with Tris-buffered saline solution with Tween 20 (TBST) 
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wash buffer. Secondary incubation was made using DUAL-labeled 
polymer horseradish peroxidase (K4061; DAKO Corp.) for 15 min. 
The slides were rinsed with TBST wash buffer. Sections were 
then incubated in 3,3′-diaminobenzidine (K3467; DAKO Corp.) for 
5 min, counterstained with modified Schmidt hematoxylin for 5 
min, rinsed for 3 min in tap water to blue sections, dehydrated with 
graded alcohols, and cleared in three changes of xylene before 
mounting. Positively stained CD68 and YKL-40 depositions were 
evaluated from a representative cross-sectional intramyocardial 
artery selected randomly from the left anterior ventricular wall, 
right ventricular wall, and septum. The evaluation was performed 
by two investigators blinded to the study protocol.
Quantitative RT-PCR analysis
The frozen tissue of the base of the heart of six randomly 
selected hearts from each group was homogenized, and RNA 
extraction was performed using GenElute™ Mammalian Total 
RNA Miniprep kit (Sigma-Aldrich, St. Louis, MO, USA) with pro-
teinase K treatment. Total RNA was then reverse-transcribed to 
cDNA using TaqMan® Reverse Transcription reagents and ran-
dom hexamers (Applied Biosystems). The cDNA obtained from 
the RT reaction (amount corresponding to approximately 1 ng of 
total RNA) was subjected to quantitative PCR using QuantiTect® 
Primer Assays (Qiagen, Valencia, CA, USA) for ANP, MMP9, TGFβ, 
YKL-40, BNP, iNOS, IL-6, VEGFα, and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH); Maxima® SYBR Green/ROX qPCR 
Master Mix (Thermo Fisher Scientific, Waltham, MA, USA); and 
ABI PRISM 7000 Sequence detection system (Applied Biosys-
tems). The PCR reaction parameters for SYBR® Green detection 
were as follows: incubation at 50 °C for 2 min and 95 °C for 10 
min, 40 cycles of denaturation at 95 °C for 15 s, and annealing 
and extension at 60 °C for 1 min. Each sample was determined 
in duplicate. The Ct values were determined, and the relative 
quantification was calculated using the 2−ΔΔCt method (15). The 
values of six control samples were used as a calibrator, and the 
expression levels of HIF1α, ANP, BNP, iNOS, IL-6, VEGFα, MMP9, 
TGFβ, and YKL-40 were normalized against GAPDH.
Statistical analysis
Data are presented as median (Q1-Q3). Statistical analyses 
were performed using the SPSS 22.0 statistical software (SPSS 
Inc., Chicago, IL, USA). For multiple comparison, data between 
the groups were analyzed using the Kruskal-Wallis test and con-
firmed using the Mann-Whitney U test, when appropriate. A p-
value <0.05 was considered significant.
Results
Histology
The presence of subendocardial and myocardial edema, 
hemorrhage, myocardial inflammation and ischemia of the ven-
tricles did not differ in the hearts with AVO+Mo as compared 
with AVO. After 1 day, the absolute number of normal nuclei 
of intramyocardial arteries in the right ventricle was higher in 
AVO+Mo than in AVO and controls [60.00 (32.25–95.50) vs. 32.50 
(21.25–38.50) and 28.50 (24.50–34.75), point score unit (PSU), 
p=0.008, Table 1]. After 3 days, the absolute number of ischemic 
Table 1. Histology of medial cell nuclei of intramyocardial arteries of the hearts with AVO after 1 and 3 days compared with 
AVO+Mo
                                            Day 1                                         Day 3
 Controls AVO AVO+Mo P-value AVO AVO+Mo P-value
Right ventricle
 Normal nuclei 28.50 (24.50-34.75) 32.50 (21.25-38.50) 60.00 (32.25-95.50) 0.008* 38.00 (31.00-40.00) 44.00 (36.25-77.00) 0.385
 Ischemic nuclei 1 (0-3.50) 2.50 (1.00-4.00) 2.00 (1.25-7.50) 0.808 3.00 (1.00-5.00) 1.50 (1.00-6.25) 0.636
 Edematous nuclei 2.00 (0.75--6.25) 3.00 (1.00-5.75) 2.50 (1.00-5.50) 0.826 0 (0-2.00) 3.00 (0.25-7.00) 0.038*
Left ventricle
 Normal nuclei 46.00 (30.00-66.25) 45.00 (36.00-63.00) 58.00 (48.75-71.75) 0.074 53.00 (51.00-69.00) 42.00 (33.25-61.25) 0.115
 Ischemic nuclei 2.00 (1.00-2.00) 3.00 (2.00-5.00) 4.00 (2.00-8.00) 0.478 5.00 (3.25-9.00) 2.00 (1.00-4.50) 0.026*
 Edematous nuclei 4.00 (0.75--10.00) 2.00 (0-5.00) 1.50 (1.00-4.50) 0.732 0.50 (0-1.00) 1.00 (0.25-3.25) 0.259
Septum
 Normal nuclei 31.00 (19.25-44.25) 39.00 (24.00-50.00) 36.00 (22.00-46.00) 0.885 39.00 (28.25-48.25) 36.00 (22.00-43.00) 0.668
 Ischemic nuclei 1.00 (0-2.25) 3.50 (2.00-7.00) 5.00 (3.00-6.00) 0.635 5.00 (3.00-7.50) 3.00 (2.00-4.00) 0.128
 Edematous nuclei 3.00 (0-5.75) 4.00 (2.00-8.00) 3.00 (3.00-6.00) 0.747 0.50 (0-1.25) 3.00 (2.00-10.00) 0.009*
Values are expressed as median (Q1–Q3). Results of multiple comparison including Kruskal–Wallis test confirmed with Mann–Whitney U test, when appropriate. Differences with a 
P-value <0.05 were considered significant. 
AVO - acute volume overload; Mo - moclobemide
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nuclei of intramyocardial arteries in the left ventricle was lower 
in AVO+Mo than in AVO and controls [2.00 (1.00–4.50) vs. 5.00 
(3.25–9.00) and 2.00 (1.00–2.00), PSU, p=0.026, Fig. 1], and the rela-
tive number of ischemic nuclei of intramyocardial arteries in the 
left ventricle was lower in AVO+Mo than in AVO [0.04 (0.02–0.07) 
vs. 0.09 (0.07–0.14), PSU, p=0.036, Fig. 2]. The presence of edem-
atous nuclei of myocardial arteries in the right ventricle and 
septum was higher in AVO+Mo than in AVO and controls [3.00 
(0.25–7.00) vs. 0 (0–2.00) and 2.00 (0.75–6.25), PSU, p=0.038 and 
3.00 (2.00–10.00) vs. 0.50 (0–1.25) and 3.00 (0–5.75), PSU, p=0.009]. 
The relative number of edematous nuclei of myocardial arteries 
in the right ventricle and septum was higher in AVO+Mo than in 
AVO [0.07 (0.01–0.12) vs. 0 (0–0.05), PSU, p=0.038 and 0.18 (0.03–
0.23) vs. 0.02 (0–0.03), PSU, p=0.010].
Immunohistochemistry
CD68 and YKL-40 were equally distributed in both AVO and 
AVO+Mo (Fig. 3).
Quantitative RT-PCR analysis
ANP was lower after 1 day in AVO+Mo than in AVO and con-
trols [0.95 (0.37–1.84) vs. 2.40 (1.33–3.09) and 0.96 (0.38–9.6), FC, 
p=0.044, Table 2], whereas YKL-40 was higher after 1 and 3 days 
in AVO+Mo than in AVO and controls [22.66 (14.05–28.83) vs. 10.06 
Figure 1. Representative histology of a septal intramyocardial artery of 
a normal heart (a; control), hearts with acute volume overload 1 day 
(b; AVO 1 day) and 3 days (c; AVO 3 days) after surgery, and hearts with 
acute volume overload and moclobemide 1 day (d; AVO+Mo 1 day) and 
3 days (e; AVO+Mo 3 days) after surgery (×40 magnification). Note the 




Figure 2. Relative ischemia of intramyocardial arteries of the septum (a), 
right ventricle (b), and left ventricle (c) of the hearts with acute volume 
overload 1 day (AVO 1 day, white triangles), treated with moclobemide 
(AVO+Mo 1 day, black triangles), hearts with acute volume overload 
3 days (AVO 3 days, white squares), and treated with moclobemide 
(AVO+Mo 3 days, black squares). *P<0.05, Mann-Whitney. Horizontal 




















AVO day 1+Mo AVO day 3 AVO day 3+Mo
a
AVO 1
Relative ischemia of right intramyocardial arteries



















Relative ischemia of left intramyocardial arteries






















Monoamine oxidase and cardiac volume overload
Anatol J Cardiol 2019; 21: 39-45
DOI:10.14744/AnatolJCardiol.2018.37336 43
(6.23–15.02) and 0.75 (0.58–0.98), FC, p=0.006 and 6.03 (4.72–7.18) 
vs. 3.70 (2.62–5.35) and 0.75 (0.58–0.98), FC, p=0.025].
Discussion
In the present study, Mo decreased the number of ischemic 
nuclei of intramyocardial arteries of the left ventricle while pre-
serving the number of normal and edematous nuclei of the right 
ventricle and septum after AVO.
We separately investigated the histology of three different 
compartments of the heart to demonstrate the interactive con-
nection between the ventricles during AVO. In this model, AVO 
leads to a dramatic burst of blood to the right side of the heart, 
pushing the septum toward the left side of the heart at day 3, 
thus inducing ischemia of intramyocardial arteries along with cel-
lular swelling of the left ventricle. The whole of the heart eventually 
results in early myocardial remodeling associated with ischemia 
and release of ROS. The generated ROS are responsible for many 
signaling responses, including activation of tyrosine kinase recep-
tors, sphingolipid pathway, transcription factors, and activation of 
proapoptotic pathways with caspase activation and calcium de-
regulation, among others (6). Among these, oxidation of biogenic 
amines by MAO may at least partly influence the association of 
ROS and ischemia with the trigger of alteration of myocardial ar-
teries (6). The development of subsequent cardiac hypertrophy is 
associated with the presence of MAO and hydrogen peroxidase 
production by oxidative stress (9).
Figure 3. Representative immunohistochemistry for CD68 deposition (a) and YKL-40 (b) in the hearts with acute volume overload and moclobemide 
3 days after surgery (×40 magnification). Arrows show positive staining
a b
Table 2. Gene expression of the hearts with AVO+Mo at 1 and 3 days compared with AVO
                                             Day 1                                          Day 3
  Controls AVO AVO+Mo P-value AVO AVO+Mo P-value
HIF1α 0.92 (0.84-1.04) 1.29 (0.77-1.82) 1.51 (1.22-2.00) 0.574 1.25 (1.02-1.41) 1.30 (1.07-1.44) 0.600
iNOS 0.82 (0.28-1.31) 1.20 (0.73-5.00) 1.01 (0.62-2.34) 0.336 0.96 (0.52-0.96) 0.70 (0.56-1.15) 0.749
E-selectin 0.97 (0.59-1.62) 2.90 (2.12-6.12) 4.19 (3.75-6.55) 0.193 1.64 (1.36-2.88) 3.31 (2.56-3.88) 0.079
ANP 0.96 (0.38-9.6) 2.40 (1.33-3.09) 0.95 (0.37-1.84) 0.044* 1.38 (0.97-2.93) 1.27 (0.88-1.38) 0.418
BNP 1.03 (1.01-1.11) 0.97 (0.38-3.25) 0.63 (0.40-1.65) 0.335 0.68 (0.58-0.98) 0.65 (0.43-1.09) 0.908
VEGFα 0.90 (0.81-1.00) 0.61 (0.34-0.88) 0.65 (0.47-0.82) 0.821 1.31 (0.80-1.68) 1.48 (1.33-1.65) 0.462
MMP9 0.69 (0.37-1.77) 9.02 (2.62-15.54) 10.55 (3.58-15.19) 0.914 4.76 (3.63-7.88) 9,68 (5.12-11.41) 0.200
YKL-40 0.75 (0.58-0.98) 10.06 (6.23-15.02) 22.66 (14.05-28.83) 0.006* 3.70 (2.62-5.35) 6.03 (4.72-7.18) 0.025*
TGFβ 1.01 (0.70-1.26) 1.90 (3.76-5.12) 3.62 (3.03-4.72) 0.792 2.69 (2.23-3.89) 3.82 (2.61-5.20) 0.121
Values are expressed as median (Q1–Q3). Results of multiple comparison including Kruskal–Wallis test confirmed with Mann–Whitney U test, when appropriate. Differences with a 
P-value <0.05 were considered significant.
AVO - acute volume overload; Mo - moclobemide; HIF1α - hypoxia-inducible factor 1-alpha; iNOS - inducible nitric oxide synthase; ANP - atrial natriuretic peptide; BNP - brain 
natriuretic peptide; VEGFα - vascular endothelial growth factor-alpha; MMP9 - matrix metalloproteinase 9; YKL-40 - chitinase 3-like protein; TGFβ - tumor growth factor β
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The generation of ROS is associated with the sphingolipid 
pathway that may mediate the association of MAO with AVO. The 
mitochondrial MAO-A metabolizes serotonin, which is released 
by activated platelets during AVO. Vascular smooth muscle cell 
proliferation is dependent on serotonin metabolism (16) and MAO 
(17). The target of MAO inhibition is the mitochondria that react 
upon AVO; selective MAO inhibition blocks the release of hydro-
gen peroxide and concomitant production of detrimental ROS 
(18). Edematous nuclei of intramyocardial arteries of the right 
ventricle and septum are preserved with concomitant decrease 
of ischemic nuclei of the left ventricle during Mo. Thus far at day 
1, Mo increased the number of normal nuclei of intramyocardial 
arteries, suggesting the preservation of cellular integrity.
Of note, Mo did not impact on inflammation during the early 
phase of AVO; periadventitial inflammation of intramyocardial ar-
teries was even undetected. There were no differences in the 
expressions of inflammatory parameters, such as E-selectin, 
MMP9, TGFβ, and VEGFα, in the hearts treated with Mo as com-
pared with the controls. All hearts with AVO showed positive im-
munohistochemical staining for CD68 and YKL-40. However, the 
tissue expression of YKL-40 was higher, while ANP was lower 
in the hearts with AVO+Mo than in those with untreated AVO. In-
stead of interacting with inflammation per se, Mo may regulate 
the inflammatory macrophages toward the M2 phenotype that 
has a strong remodeling capacity.
An increased serum YKL-40 may indicate excessive cleav-
age of the glycoprotein-like molecule on the endothelium of the 
intramyocardial arteries, suggesting an increased activation of 
proinflammatory and profibrotic cytokines after ischemia (19). 
Alternately, the expression of tissue YKL-40 is a sign of tissue 
remodeling after ischemia (20-22). YKL-40 has an angiogenic 
property that may preserve the cells from apoptosis and cell 
death (23). It inhibits inflammation and cell apoptosis by de-
creasing Fas expression, activating protein kinase B/protein 
kinase B, and inducing Faim 3 (20). It regulates the intensity of 
T helper cell 2 (Th2)-dominated diseases while increases the 
accumulation of T cells and alternatively activates M2 macro-
phages (20). Interestingly, the Th2 cytokines, IL-4 and IL-13, also 
polarize macrophages toward the YKL-40-producing M2 pheno-
type macrophages (24).
Nevertheless, the exact mechanisms associated with MAO-A 
inhibition during AVO remain to be elucidated. The selected gene 
expressions reflected the overall outcome after AVO. Previous-
ly, the activation of the mitochondrial electron transport chain, 
NADPH oxidase, and xanthine oxidase has been speculated to 
increase during ROS generation after AVO. However, ischemia 
may occur in the organs known to be deficient for xanthine oxi-
dase and in a mouse model without a functional NADPH oxidase 
(18). The sphingolipid pathway seems therefore plausible in our 
model; MAO regulates through ROS the lipid peroxidation of cell 
membranes, protein and enzyme oxidation, and some irreversible 
DNA changes leading to cell death (18). In a recent experimental 
study by Sturza et al. (5), MAOs are shown to be responsible for 
vascular damage by decreasing peroxidation and endothelial ni-
tric oxide release.
Study limitations
The limitations of the present study include the plausible in-
teraction with catecholamine metabolism due to MAO inhibition 
(25). We therefore chose Mo, a selective and reversible MAO 
inhibitor. The reversibility of MAO inhibition may abolish the pos-
sible side effects due to catecholamine metabolism. In addition, 
cardioprotection may be induced via autophagy after myocardial 
damage, and inducing autophagy sequestration may lead to nov-
el therapeutic options against myocardial ischemia (26). Future 
investigation of plasma parameters for myocardial damage and 
oxidative stress is recommended. We did not measure the left 
ventricular ejection fraction to describe cardiac function. AVO 
includes a dispersed range of histological findings necessitating 
the careful statistical interpretation of the results. The results 
should be cautiously interpreted; the findings and conclusions 
should not be simply translated to humans in the real clinical set-
ting.
Conclusion
In conclusion, MAO may be associated with AVO. We suggest 
further studies of MAO inhibition after AVO. Despite these prom-
ising experimental results, clinical studies will be necessary to 
evaluate the therapeutic properties of MAO inhibitors after AVO, 
especially in the organs, such as the heart, containing a large 
amount of MAOs.
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